FARMABIOS S.P.A Fails EDQM Inspection
Enforcement Report - Week of October 31, 2018
Recipharm Ltd. Fails EDQM Inspection
Enforcement Report - Week of July 5, 2017
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced plans to launch its IV Free™ MKO Melt™ conscious sedation formulations and new triple combination eye drop that includes nepafenac at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016.
On January 13, 2016, India’s NPPA issued an Order (S.O. 117(E)), effectively immediately that withdrew the previously issued October 29, 2015 Order (S.O. 2947(E)) which had set the fixed retail price of Rs. 3.69 for Akums Drugs & Pharmaceuticals Ltd (manufacturer) and Entod Pharmaceuticals Ltd.’s (marketer) formulation of Moxifloxacin + Prednisolone Acetate for 1ml.
Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops